Supernus Pharmaceuticals, Inc.

NasdaqGM:SUPN Voorraadrapport

Marktkapitalisatie: US$2.1b

Supernus Pharmaceuticals Beheer

Beheer criteriumcontroles 2/4

De CEO Supernus Pharmaceuticals is Jack Khattar, benoemd in Jan2005, heeft een ambtstermijn van 19.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 13.28M, bestaande uit 7.3% salaris en 92.7% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 3.53% van de aandelen van het bedrijf, ter waarde $ 73.56M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 9.6 jaar en 12.3 jaar.

Belangrijke informatie

Jack Khattar

Algemeen directeur

US$13.3m

Totale compensatie

Percentage CEO-salaris7.3%
Dienstverband CEO19.8yrs
Eigendom CEO3.5%
Management gemiddelde ambtstermijn9.6yrs
Gemiddelde ambtstermijn bestuur12.3yrs

Recente managementupdates

Recent updates

Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Share Price Could Signal Some Risk

Oct 31
Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Share Price Could Signal Some Risk

Supernus: Stock Slides As Qelbree Sales Questioned, But Positives Still Outweigh Negatives

Sep 12

Supernus Pharmaceuticals' (NASDAQ:SUPN) Conservative Accounting Might Explain Soft Earnings

Aug 19
Supernus Pharmaceuticals' (NASDAQ:SUPN) Conservative Accounting Might Explain Soft Earnings

Supernus Pharmaceuticals: So-So Neuroscience Portfolio, With ADHD Standout

Jul 02

Subdued Growth No Barrier To Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Price

Apr 24
Subdued Growth No Barrier To Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Price

Supernus Pharmaceuticals: Moving Through An 'Inflection Year'

Mar 04

We Think Supernus Pharmaceuticals (NASDAQ:SUPN) Can Stay On Top Of Its Debt

May 10
We Think Supernus Pharmaceuticals (NASDAQ:SUPN) Can Stay On Top Of Its Debt

Does Supernus Pharmaceuticals (NASDAQ:SUPN) Have A Healthy Balance Sheet?

Feb 03
Does Supernus Pharmaceuticals (NASDAQ:SUPN) Have A Healthy Balance Sheet?

These 4 Measures Indicate That Supernus Pharmaceuticals (NASDAQ:SUPN) Is Using Debt Reasonably Well

Oct 19
These 4 Measures Indicate That Supernus Pharmaceuticals (NASDAQ:SUPN) Is Using Debt Reasonably Well

Supernus stock falls 12.6% after FDA declines to approve Parkinson’s disease treatment

Oct 10

Supernus Pharmaceuticals: Deep Expertise In CNS, Eyes On Qelbree Launch And Parkinson Portfolio

Aug 19

Supernus Pharmaceuticals' (NASDAQ:SUPN) Soft Earnings Are Actually Better Than They Appear

Aug 16
Supernus Pharmaceuticals' (NASDAQ:SUPN) Soft Earnings Are Actually Better Than They Appear

Supernus: A Work In Progress

Jul 29

Supernus: New Beginnings

Mar 28

Brokers Are Upgrading Their Views On Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) With These New Forecasts

Dec 02
Brokers Are Upgrading Their Views On Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) With These New Forecasts

Analyse CEO-vergoeding

Hoe is Jack Khattar's beloning veranderd ten opzichte van Supernus Pharmaceuticals's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Sep 30 2024n/an/a

US$60m

Jun 30 2024n/an/a

US$5m

Mar 31 2024n/an/a

-US$16m

Dec 31 2023US$13mUS$963k

US$1m

Sep 30 2023n/an/a

US$26m

Jun 30 2023n/an/a

US$43m

Mar 31 2023n/an/a

US$52m

Dec 31 2022US$10mUS$914k

US$61m

Sep 30 2022n/an/a

US$38m

Jun 30 2022n/an/a

US$57m

Mar 31 2022n/an/a

US$73m

Dec 31 2021US$8mUS$870k

US$53m

Sep 30 2021n/an/a

US$82m

Jun 30 2021n/an/a

US$100m

Mar 31 2021n/an/a

US$111m

Dec 31 2020US$7mUS$836k

US$127m

Sep 30 2020n/an/a

US$129m

Jun 30 2020n/an/a

US$118m

Mar 31 2020n/an/a

US$116m

Dec 31 2019US$8mUS$812k

US$113m

Sep 30 2019n/an/a

US$106m

Jun 30 2019n/an/a

US$105m

Mar 31 2019n/an/a

US$103m

Dec 31 2018US$7mUS$724k

US$111m

Sep 30 2018n/an/a

US$99m

Jun 30 2018n/an/a

US$87m

Mar 31 2018n/an/a

US$73m

Dec 31 2017US$6mUS$614k

US$57m

Compensatie versus markt: De totale vergoeding ($USD 13.28M ) Jack } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 5.36M ).

Compensatie versus inkomsten: De vergoeding van Jack is het afgelopen jaar met meer dan 20% gestegen.

CEO

Jack Khattar (63 yo)

19.8yrs

Tenure

US$13,278,093

Compensatie

Mr. Jack A. Khattar, M.B.A., founded Supernus Pharmaceuticals, Inc. (Formerly, Shire Laboratories, Inc.) in 2005 and has served as Chief Executive Officer, President, Secretary and Director since 2005. He...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Jack Khattar
Founder19.8yrsUS$13.28m3.53%
$ 73.6m
Timothy Dec
Senior VP & CFO3.3yrsUS$2.38m0.013%
$ 271.4k
Padmanabh Bhatt
Chief Scientific Officer & Senior VP of Intellectual Property12.7yrsUS$1.47m0.018%
$ 365.4k
Frank Mottola
Senior Vice President of Quality4.8yrsUS$1.79m0.014%
$ 293.7k
Jonathan Rubin
Senior VP of Research & Development and Chief Medical Officer4.8yrsUS$1.59m0.0084%
$ 175.1k
Kevin Anderson
Compliance Officer12.8yrsgeen gegevensgeen gegevens
Todd Horich
Senior Vice President of Marketing9.8yrsgeen gegevensgeen gegevens
Taylor Raiford
Senior Vice President of Sales9.8yrsgeen gegevensgeen gegevens
Bryan Roecklein
Senior Vice President of Corporate Development9.3yrsgeen gegevensgeen gegevens
Jeff Bozick
Senior Vice President of Supply Chain3.5yrsgeen gegevensgeen gegevens

9.6yrs

Gemiddelde duur

63yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van SUPN is doorgewinterd en ervaren (gemiddelde ambtstermijn van 9.6 jaar).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Jack Khattar
Founder19.8yrsUS$13.28m3.53%
$ 73.6m
Charles Newhall
Independent Chairman of the Board19.8yrsUS$407.02k0.22%
$ 4.6m
Georges Gemayel
Independent Director9.7yrsUS$378.52k0.024%
$ 502.6k
Carrolee Barlow
Independent Director6.4yrsUS$376.02k0.031%
$ 649.3k
Frederick Hudson
Independent Director14.8yrsUS$385.02k0.067%
$ 1.4m
Bethany Sensenig
Directorless than a yearUS$514.39kgeen gegevens

12.3yrs

Gemiddelde duur

63.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van SUPN zijn ervaren en ervaren (gemiddelde ambtstermijn van 12.3 jaar).